U.S., Sept. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07164469) titled 'Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma' on Sept. 04.
Brief Summary: This clinical research study is to learn if CD70.CAR NK cell therapy can help to control early relapsed or primary refractory DLBCL and cHL.
Study Start Date: Feb. 28, 2026
Study Type: INTERVENTIONAL
Condition:
Large B-cell Lymphoma
Hodgkin Lymphoma
Intervention:
DRUG: Fludarabine
Given by IV
DRUG: Cyclophosphamide
Given by IV
DRUG: CD70.CAR NK Cells
Given by IV Infusion
DRUG: Rimiducid (AP1903)
Given by IV Infusion
Recruitment Status: NOT_YET_RECRUIT...